Citations to this article

Federica Di Nicolantonio, Sabrina Arena, Josep Tabernero, Stefano Grosso, Francesca Molinari, Teresa Macarulla, Mariangela Russo, Carlotta Cancelliere, Davide Zecchin, Luca Mazzucchelli, Takehiko Sasazuki, Senji Shirasawa, Massimo Geuna, Milo Frattini, José Baselga, Margherita Gallicchio, Stefano Biffo, Alberto Bardelli
Published in Volume 120, Issue 8
J Clin Invest. 2010; 120(8):2858–2866 doi:10.1172/JCI37539

Total citations by year in Crossref

Year: 2014 2013 2012 2011 Total
Citations: 15 21 14 13 63
Citation information

Citations to this article in Crossref (63)

Title and authors Publication Year
mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: A critical review
N Husseinzadeh, HD Husseinzadeh
Gynecologic Oncology 2014
Dual Inhibition of Phosphatidylinositol 3′-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach for Mucinous Adenocarcinoma of the Ovary:
A Kudoh, T Oishi, H Itamochi, S Sato, J Naniwa, S Sato, M Shimada, J Kigawa, T Harada
International Journal of Gynecological Cancer 2014
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
J Rodon, I Braña, LL Siu, MJ Jonge, N Homji, D Mills, E Tomaso, C Sarr, L Trandafir, C Massacesi, F Eskens, JC Bendell
Investigational New Drugs 2014
Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment
H Cheng, M Shcherba, G Pendurti, Y Liang, B Piperdi, R Perez-Soler
Lung Cancer Management 2014
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
J Polivka, F Janku
Pharmacology & Therapeutics 2014
Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors
F Janku, DS Hong, S Fu, SA Piha-Paul, A Naing, GS Falchook, AM Tsimberidou, VM Stepanek, SL Moulder, JJ Lee, R Luthra, RG Zinner, RR Broaddus, JJ Wheler, R Kurzrock
Cell Reports 2014
Analysis of Molecular Cytogenetic Changes in Metastatic Renal Cell Carcinoma in the Setting of Everolimus Treatment: A Pilot Project
IR Caldwell, P Oei, D Ng, B Caudwell, PC Fong, RJ Broom
Clinical Genitourinary Cancer 2014
Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends
MS Matter, T Decaens, JB Andersen, SS Thorgeirsson
Journal of Hepatology 2014
A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: A Gynecologic Oncology Group study
SM Campos, WE Brady, KM Moxley, RE O'Cearbhaill, PS Lee, PA DiSilvestro, J Rotmensch, PG Rose, PH Thaker, DM O'Malley, P Hanjani, RE Zuna, ML Hensley
Gynecologic Oncology 2014
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study
M Wang, LL Popplewell, RH Collins, JN Winter, A Goy, MS Kaminski, NL Bartlett, PB Johnston, J Lister, SR Fanning, JM Tuscano, JT Beck, H Kaya, A Robeva, J Fan, J Klimovsky, W Cheung, A Cherfi, OA O'Connor
British Journal of Haematology 2014
Predictive biomarker candidates for the response of gastric cancer to targeted and cytotoxic agents
HK Kim, JE Green
Pharmacogenomics 2014
Precision medicine for metastatic renal cell carcinoma
G Sonpavde, TK Choueiri
Urologic Oncology: Seminars and Original Investigations 2014
PIK3CA Mutations in Mucinous Cystic Neoplasms of the Pancreas:
D Garcia-Carracedo, ZM Chen, W Qiu, AS Huang, SM Tang, RH Hruban, GH Su
Pancreas 2014
PI3K/AKT signaling pathway and cancer: an updated review
M Martini, MC de Santis, L Braccini, F Gulluni, E Hirsch
Annals of Medicine 2014
The Search Continues: Looking for Predictive Biomarkers for Response to Mammalian Target of Rapamycin Inhibition in Endometrial Cancer
LA Meyer, BM Slomovitz, B Djordjevic, SN Westin, DA Iglesias, MF Munsell, Y Jiang, R Schmandt, RR Broaddus, RL Coleman, JM Galbincea, KH Lu
International Journal of Gynecological Cancer 2014
Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: Outcome and results of KRAS mutational analysis in plasma
KL Spindler, MM Sorensen, N Pallisgaard, RF Andersen, BM Havelund, J Ploen, U Lassen, AK Jakobsen
Acta Oncologica 2013
Characterization of mechanism involved in acquired resistance to sorafenib in a mouse renal cell cancer RenCa model
K Harada, H Miyake, Y Kusuda, M Fujisawa
Clinical and Translational Oncology 2013
Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2
K Harada, H Miyake, M Kumano, M Fujisawa
British Journal of Cancer 2013
Tailoring mTOR-based therapy: molecular evidence and clinical challenges
G Santulli, H Totary-Jain
Pharmacogenomics 2013
The potential role of new targeted therapies in the treatment of advanced non-small-cell lung cancer
F Casaluce, A Sgambato, P Maione, A Rossi, C Ferrara, A Napolitano, G Palazzolo, F Ciardiello, C Gridelli
Clinical Investigation 2013
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer
CX Ma, VJ Suman, M Goetz, P Haluska, T Moynihan, R Nanda, O Olopade, T Pluard, Z Guo, HX Chen, C Erlichman, MJ Ellis, GF Fleming
Breast Cancer Research and Treatment 2013
Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux
F Lin, MC de Gooijer, D Hanekamp, D Brandsma, JH Beijnen, O Tellingen
CNS Oncology 2013
Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation: Acquired resistance to sunitinib in RCC
I Sakai, H Miyake, M Fujisawa
BJU International 2013
ARID1A Mutations and PI3K/AKT Pathway Alterations in Endometriosis and Endometriosis-Associated Ovarian Carcinomas
E Samartzis, A Noske, K Dedes, D Fink, P Imesch
International journal of molecular sciences 2013
Patterns of DNA Mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma:
PY Yip, B Yu, WA Cooper, CI Selinger, CC Ng, CW Kennedy, MR Kohonen-Corish, BC McCaughan, RJ Trent, MJ Boyer, JG Kench, LG Horvath, SA O’Toole
Journal of Thoracic Oncology 2013